ArticleAdvanced biomedical research2018
Prevalence of
Article in Advanced biomedical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Antibiotic resistance profiles and co-occurrence of ESBL and AmpC β-lactamase genes in ESBL-producing Gram-negative bacteria of clinical origin.BMC microbiology · 2026Article
- Camellia sinensis-synthesized silver nanoparticles and meropenem combination against extensively drug-resistant Klebsiella pneumoniae.Scientific reports · 2026Article
- Clonal Diversity and Resistome Dynamics ofMedicina (Kaunas, Lithuania) · 2025Article
- Phenotypic and genetic screening of Klebsiella pneumoniae isolates from human UTI patients for beta-lactamases and their genetic diversity analysis by ERIC and REP PCRs.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Systematic Review and Meta-analysis on Extended-Spectrum β-lactamases ProducingMicrobiology insights · 2023Review
- EVALUATION OF PHENOTYPIC AND MOLECULAR TECHNIQUE IN THE DETECTION OF EXTENDED SPECTRUM BETA-LACTAMASE (ESBL)-PRODUCING GRAM NEGATIVE BACILLI IN OGUN STATE, NIGERIA.Annals of Ibadan postgraduate medicine · 2022Article
- Prevalence of extended-spectrum β-lactamases, AmpC, and carbapenemases in Proteus mirabilis clinical isolates.BMC microbiology · 2022Article
- Whole genome sequencing and characteristics of extended-spectrum beta-lactamase producingFrontiers in microbiology · 2022Article
- Beta-lactamase determinants and molecular typing of carbapenem-resistant classic and hypervirulentFrontiers in microbiology · 2022Article
- Co-Existence of Certain ESBLs, MBLs and Plasmid Mediated Quinolone Resistance Genes among MDRAntibiotics (Basel, Switzerland) · 2021Article
- Prevalence and molecular characteristics of ESBL and AmpC β -lactamase producing Enterobacteriaceae strains isolated from UTIs in Egypt.Antimicrobial resistance and infection control · 2020Article
- Prevalence of Extended-Spectrum β-lactamase and Integron Gene Carriage in Multidrug-ResistantIranian journal of medical sciences · 2020Article
- Preliminary survey of extended-spectrum β-lactamases (ESBLs) in nosocomial uropathogenHeliyon · 2019Article
- Understanding the Epidemiology of Multi-Drug Resistant Gram-Negative Bacilli in the Middle East Using a One Health Approach.Frontiers in microbiology · 2019Review
- High frequency of simultaneous presence of ESBL and carbapenemase producers among nosocomial coliform isolates in Faisalabad, Pakistan.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtended-spectrum β-lactamase (ESBL)-producing is a significant resistant mechanism to β-lactams in MATERIALS AND
methodsA cross-sectional study was carried out to evaluate 98 strains of
resultsIn 98
conclusionThis study revealed high antimicrobial resistance rates among ESBL isolates which can lead to various health difficulties. Epidemiological data collection from patients is recommended to develop the strategies to manage antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.